CLINICAL_TRIALS ClinicalTrials.gov record update

Reduced-Intensity Preparative Regiment With Fludarabine, Busulfan, And Alemtuzumab (Campath 1H) Followed By Allogeneic Hematopoietic Stem Cell Transplant For Malignant And Non-Malignant Hematological Diseases

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00579111
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:13.557676+00:00
Published At: 2012-08-09T00:00:00+00:00
Record Updated At: 2016-05-04
Results Posted At: 2012-08-09
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Myelodysplastic and Myeloproliferative Disorders", "Acute Myelogenous Leukemia", "Acute Lymphoblastic Leukemia", "Chronic Myelogenous Leukemia", "Multiple Myeloma", "Plasma Cell Dyscrasia", "Lymphoproliferative Disorders", "Hematologic Diseases"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2016-05-04"
protocolSection.identificationModule.nctId: "NCT00579111"
protocolSection.identificationModule.officialTitle: "Reduced-Intensity Preparative Regiment With Fludarabine, Busulfan, And Alemtuzumab (Campath 1H) Followed By Allogeneic Hematopoietic Stem Cell Transplant For Malignant And Non-Malignant Hematological Diseases"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2012-08-09"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.